7. Fujiuchi S, Ohsaki Y, Kikuchi K (1997) Suramin inhibits the growth of non- small-cell lung cancer cells that express the epidermal growth factor receptor. Oncology 54: 134–140. 8. Abdiu A, Larsson SE, Wasteson A, Walz TM (1999) Suramin blocks growth- stimulatory effects of platelet-derived growth factor on malignant fibrous histiocytomas in vitro. Cancer Lett 146: 189–194. 9. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499–508. 10. Braunstein J, Brutsaert S, Olson R, Schindler C (2003) STATs dimerize in the absence of phosphorylation. J Biol Chem 278: 34133–34140. 11. Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, et al. (2009) Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58: 469–477. 12. Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, et al. (2011) Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 22: 1064–1075. 13. Liu N, Tolbert E, Ponnusamy M, Yan H, Zhuang S (2011) Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy. J Pharmacol Exp Ther 338: 758–766. 14. Diamond JR, Pesek-Diamond I (1991) Sublethal X-irradiation during acute puromycin nephrosis prevents late renal injury: role of macrophages. Am J Physiol 260: F779–786. 15. van Goor H, van der Horst ML, Fidler V, Grond J (1992) Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest 66: 564–571. 16. Waldherr R, Gretz N (1988) Natural course of the development of histological lesions after 5/6 nephrectomy. Contrib Nephrol 60: 64–72. 17. Fogo A, Ichikawa I (1989) Evidence for the central role of glomerular growth promoters in the development of sclerosis. Semin Nephrol 9: 329–342. 18. Nikolic-Paterson DJ, Atkins RC (2001) The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16 Suppl 5: 3–7. 19. Shimizu H, Maruyama S, Yuzawa Y, Kato T, Miki Y, et al. (2003) Anti- monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 14: 1496–1505. 20. Timoshanko JR, Kitching AR, Semple TJ, Holdsworth SR, Tipping PG (2005) Granulocyte macrophage colony-stimulating factor expression by both renal parenchymal and immune cells mediates murine crescentic glomerulonephritis. J Am Soc Nephrol 16: 2646–2656. 21. Daha MR, van Kooten C (2000) Is the proximal tubular cell a proinflammatory cell? Nephrol Dial Transplant 15 Suppl 6: 41–43. 22. Anders HJ, Vielhauer V, Schlondorff D (2003) Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 63: 401–415. 23. Segerer S, Nelson PJ, Schlondorff D (2000) Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11: 152–176. 24. Behrens MT, Corbin AL, Hise MK (1989) Epidermal growth factor receptor regulation in rat kidney: two models of renal growth. Am J Physiol 257: F1059–1064. 25. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, et al. (1992) Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297–309. 26. Li J, Zhang Z, Wang D, Wang Y, Li Y, et al. (2009) TGF-beta 1/Smads signaling stimulates renal interstitial fibrosis in experimental AAN. J Recept Signal Transduct Res 29: 280–285. 27. Pang M, Ma L, Gong R, Tolbert E, Mao H, et al. (2010) A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78: 257–268. 28. Lange-Sperandio B, Trautmann A, Eickelberg O, Jayachandran A, Oberle S, et al. (2007) Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice. Am J Pathol 171: 861–871. 29. Krensky AM, Ahn YT (2007) Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 3: 164–170. 30. Guijarro C, Egido J (2001) Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 59: 415–424. Suramin Attenuates Renal Fibrosis 31. Kakuta Y, Okumi M, Isaka Y, Tsutahara K, Abe T, et al. (2011) Epigallocatechin-3-gallate protects kidneys from ischemia reperfusion injury by HO-1 upregulation and inhibition of macrophage infiltration. Transpl Int 24: 514–522. 32. Cho MH (2010) Renal fibrosis. Korean J Pediatr 53: 735–740. 33. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, et al. (2004) Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoat- tractant protein-1 and RANTES. J Am Soc Nephrol 15: 2868–2881. 34. Wada T, Yokoyama H (2006) [Molecular biology in regulation of kidney functions: MCP-1/CCR2]. Nihon Rinsho 64 Suppl 2: 288–292. 35. Ivashkiv LB (2011) Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation states. Eur J Immunol 41: 2477–2481. 36. Sabatel H, Pirlot C, Piette J, Habraken Y (2011) Importance of PIKKs in NF- kappaB activation by genotoxic stress. Biochem Pharmacol 82: 1371–1383. 37. Chen Y, Kijlstra A, Yang P (2011) IL-17A stimulates the production of inflammatory mediators via Erk1/2, p38 MAPK, PI3K/Akt, and NF-kappaB pathways in ARPE-19 cells. Mol Vis 17: 3072–3077. 38. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, et al. (2011) Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 208: 1359–1366. 39. Melenhorst WB, Mulder GM, Xi Q, Hoenderop JG, Kimura K, et al. (2008) Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension 52: 987–993. 40. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, et al. (2005) Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11: 867–874. 41. Ludewig D, Kosmehl H, Sommer M, Bohmer FD, Stein G (2000) PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res 299: 97–103. 42. Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15: 255–273. 43. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, et al. (2000) Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo- interstitial lesions after renal injury. J Clin Invest 106: 225–234. 44. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199–210. 45. Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69: 213–217. 46. Bidani AK, Griffin KA, Bakris G, Picken MM (2000) Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 57: 1651–1661. 47. Harris KP, Baker F, Brown J, Walls J (1993) Early increase in glomerular leucocyte number after a reduction in renal mass: implications for the pathogenesis of glomerulosclerosis. Clin Sci (Lond) 85: 27–31. 48. Pawluczyk IZ, Harris KP (1997) Macrophages promote prosclerotic responses in cultured rat mesangial cells: a mechanism for the initiation of glomerulosclerosis. J Am Soc Nephrol 8: 1525–1536. 49. Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19: 1741–1752. 50. Sanz AB, Sanchez-Nino MD, Ramos AM, Moreno JA, Santamaria B, et al. (2010) NF-kappaB in renal inflammation. J Am Soc Nephrol 21: 1254–1262. 51. Chen S, Khan ZA, Cukiernik M, Chakrabarti S (2003) Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab 284: E1089–1097. 52. Liu N, Zhuang S (2011) Tissue protective and anti-fibrotic actions of suramin: new uses of an old drug. Curr Clin Pharmacol 6: 137–142. 53. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, et al. (2009) Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297: F996–F1005. PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e36194